30 Years of Experience: The Career of Dr Erik Goluboff.

Dr Erik Goluboff is a medical professional with a career specialization in urology. He is currently the Principal Medical Lead of Genentech’s drug development program in urologic cancers and has held high-ranking positions at notable organizations throughout his career. He received his medical degree from Johns Hopkins University in 1990 and completed his urology residency at New York-Presbyterian Hospital/Weill Cornell Medical Center. He is board certified in urology and is a fellow of the American College of Surgeons.
He has extensive experience treating urologic cancers and has been involved in the development and implementation of several new treatments for prostate cancer. He is an active researcher and is actively involved in the broader medical community. He continues to work tirelessly to find new and better ways to treat this disease and improve the quality of life for patients with urologic cancer.
Dr Erik Goluboff dedication to improving the lives of patients with urologic cancer is evident in his work. His expertise and experience in this field are widely recognized, and his contributions have been invaluable. He continues to work tirelessly to find new and better ways to treat this disease and improve the quality of life for patients with urologic cancer.
Dr Erik Goluboff began his career as an academic urologic oncologist, working at various institutions and gaining experience treating urologic cancers. He then transitioned to the pharmaceutical industry, working at AstraZeneca as a medical director and leading the development of new treatments for urologic cancers.
Dr Erik Goluboff serves as the Principal Medical Lead of Genentech’s urologic cancer drug development program. In this role, he is responsible for leading the development and execution of clinical trials for new treatments in this area. Dr Erik Goluboff’s experience in academia and the pharmaceutical industry gives him a unique perspective on developing new treatments and the needs of patients with urologic cancers.